fda compounding semaglutide warning letters october 2025 Sends to More Than 50 GLP-1 Compounders and Manufacturers The FDA has issued warning

Notably, over the subsequent 6 days, we observed a sustained body-weight-lowering effect after infusion of GLP-1MK-801, but not semaglutide, suggesting that the targeted inhibition of NMDA receptors in GLP-1 receptor-positive neurons might promote sustained changes to the defended level of adiposity

PMID 7843404

Describes potential lawsuits and regulatory investigations that could arise from marketing, prescribing, or dispensing compounded semaglutide

Synthetic GLP-1 and GIP agonists bind to their respective receptors and elicit the same response as the endogenous hormones would

Q6: Does semaglutide microdosing play a role in preserving muscle mass during fat loss